Atrogi AB, a clinical stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces that the first subjects have been dosed in a ...
Atrogi has dosed the first participants in a human study of its lead candidate ATR‑258, marking a significant step forward ...
Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic disease First-in-class oral therapy ATR-258 mimics the effects of ...
AN EXERCISE pill that mimics a workout to build muscle and burn fat has entered human patient trials for the first time. A ...
Atrogi AB is raising a €30 million to €35 million (US$32.9 million to $38.4 million) series B round after announcing positive clinical data for ATR-258, a novel beta-2 adrenergic receptor agonist that ...
First-in-class oral therapy ATR-258 mimics the effects of exercise - driving fat loss, increasing muscle, and improving metabolism - with broad potential as a novel treatment for muscle-sparing ...
Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective ß2-agonists for the first time in metabolic disease First-in-class oral therapy ATR-258 mimics the effects of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results